Pages

▼
Friday, January 29, 2021

Why aren’t therapeutic antibodies being used more to treat COVID-19?

›
By Nicholson Price , Rachel Sachs , Jacob S. Sherkow , and Lisa Larrimore Ouellette When former President Donald Trump contracted COVID-19 i...
Wednesday, January 27, 2021

Irene Calboli: Trademarking COVID

›
Irene Calboli , professor of law at Texas A&M University School of Law, has written a new empiric...
Tuesday, January 12, 2021

What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?

›
By Lisa Larrimore Ouellette , Nicholson Price , Rachel Sachs , and Jacob S. Sherkow In the middle of a record number of COVID-19 infections ...
Friday, December 18, 2020

How can policymakers encourage COVID-19 vaccine trials for children?

›
By Jacob S. Sherkow , Lisa Larrimore Ouellette , Nicholson Price , and Rachel Sachs The past two weeks have been full of exciting COVID-19 v...
Tuesday, December 15, 2020

Patents and Science Fiction: Does Science Fiction Promote Innovation?

›
Dan Brean and I have just posted a new essay called Enabling Science Fiction . We wrote the essay for the upcoming Association of American ...
Monday, November 30, 2020

What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?

›
By Rachel Sachs , Jacob S. Sherkow , Lisa Larrimore Ouellette , and Nicholson Price When President-elect Joe Biden is inaugurated in January...
Saturday, November 21, 2020

What role is AI playing in the COVID-19 pandemic?

›
By Nicholson Price , Rachel Sachs , Jacob S. Sherkow , and Lisa Larrimore Ouellette Promising results for the Pfizer/BioNTech and Moderna v...
Monday, November 2, 2020

Trade Secrets and Prior Art

›
I have published an article entitled " The Trade Secrecy Standard for Patent Prior Art ," co-authored with Sharon K. Sandeen.  The...
Friday, October 30, 2020

What did we learn from last week’s FDA vaccine advisory committee meeting?

›
By Lisa Larrimore Ouellette , Nicholson Price , Rachel Sachs , and Jacob S. Sherkow On October 22 , the FDA’s Vaccines and Related Biologica...
Thursday, October 29, 2020

Excerpt from Masur & Ouellette's Free Patent Law Casebook (Forthcoming Summer 2021)

›
In January 2020, Jonathan Masur (Chicago Law) and I decided to write a free patent law casebook, which has turned out to be a rewarding pand...
Monday, October 12, 2020

What is—and should be—the military’s role in COVID-19 research?

›
By Jacob S. Sherkow , Lisa Larrimore Ouellette , Nicholson Price , and Rachel Sachs A recent STAT News report found that Operation Warp Spe...

Google v. Oracle and the search for an analogy

›
I had the pleasure of listening to the Supreme Court oral argument in near real-time from the comfort of my desk last Wednesday, one of the ...
Friday, October 2, 2020

How are COVID-19 vaccine manufacturers aiming to encourage trust in the FDA’s approval process?

›
By Rachel Sachs , Jacob S. Sherkow , Lisa Larrimore Ouellette , and Nicholson Price In recent weeks, a number of articles have reported grea...
Thursday, September 10, 2020

What are the innovation challenges to scaling vaccine manufacturing?

›
By Nicholson Price , Rachel Sachs , Jacob S. Sherkow , and Lisa Larrimore Ouellette Many worries dog the race for a COVID-19 vaccine. Is the...
Tuesday, August 25, 2020

Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?

›
By Lisa Larrimore Ouellette , Nicholson Price , Rachel Sachs , and Jacob S. Sherkow This week’s FDA news has been dominated by the tumultuou...